CompletedNot Applicable

Scalp Cooling in Gynecologic Cancer Patients

Hong Kong80 participantsStarted 2019-11-11

Plain-language summary

In gynecologic cancers, many common chemotherapy agents can lead to chemotherapy-induced alopecia. Currently scalp cooling is the most well studied preventive measure. However, its acceptability and its impact on patients' QOL in Asian population is unclear.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must be at least 18 years old.
✓. Patients with primary gynecologic cancers.
✓. Patients who are going to receive at least four cycles of chemotherapy that are known to induce alopecia, such as carboplatin, paclitaxel, taxotere, topotecan, etoposide, vincristine and ifosfamide.
✓. Patients who are fit to give informed consent.

Exclusion criteria

✕. Patients who have pre-existing alopecia of CTCAE v5.0 grade 1 or above will be excluded.
✕. Patients who have the following conditions will be excluded:
✕. migraine
✕. scalp or brain metastasis
✕. hypothyroidism
✕. uncontrolled diabetes
✕. liver and / or renal derangement (where liver enzymes and / or creatinine are 1.5x more than upper normal limit)
✕. severe untreated anaemia

What they're measuring

Incidence and grading of chemotherapy induced alopecia

Timeframe: 9 months

Trial details

NCT IDNCT04168242

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-30

View on ClinicalTrials.gov More Gynecologic Cancer trials